Evaluating Exenatide for the Treatment of Postprandial Hyperinsulinemic Hypoglycemia

University of Minnesota (UMN)

Status and phase: Completed; Phase 1

Conditions: Hyperinsulinemic Hypoglycemia

Treatments: Drug: Exenatide Placebo; Drug: Acarbose; Drug: Exenatide; Drug: Acarbose Placebo

Study type: Interventional

Funder types: Other

Identifiers

NCT02685852

1503M65841

Details and patient eligibility

About

The purpose of the study is to evaluate the effectiveness of exenatide in adults experiencing episodes of hyperinsulinemic hypoglycemia following Roux-en-Y bariatric surgery.

Full description

Roux-en-Y gastric bypass surgery (RYGB) is one of the most common bariatric surgeries in the United States and is generally highly effective for weight loss. Unfortunately, among the potential complications is hyperinsulinemic hypoglycemia. Though the prevalence of this disorder has not been fully characterized, it can be associated with debilitating symptoms which severely impact quality of life and can be life-threatening. The underlying pathophysiology of hyperinsulinemic hypoglycemia likely involves a mismatch in the amount of insulin secreted in response to mealtime carbohydrate absorption. It has been observed that the ingestion of a high carbohydrate load often leads to a modest rise in post-prandial glucose levels followed by an inappropriately exaggerated insulin release among individuals with this condition. Low carbohydrate diet sometimes provides full or partial relief of the symptoms.

Standard medical management for RYGB associated postprandial hyperinsulinemic hypoglycemia includes acarbose, which partially reduces carbohydrate absorption from the gut, and diazoxide, which directly inhibits insulin release from pancreatic beta cells. However, the medical options are not reliably effective, leading some individuals to reverse RYGB, which also may not be effective, or even undergo partial pancreatectomy, risking additional complications such as diabetes. Much more reliably effective treatments are needed for this special population who develop this bariatric surgical complication.

Potential mechanisms contributing to the mismatched insulin secretion post RYGB include decreased systemic and adipose tissue inflammation, and increased insulin receptor expression in liver and skeletal muscle, and increases in adiponectin.

Enrollment: 11 patients

Sex: All

Ages: 18 to 60 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. must have undergone RYGB and subsequently developed post-prandial hypoglycemia (defined as at least 3 episodes over a six-month period with documented capillary blood sugars [<60 mg/dL with hypoglycemic symptoms). Subjects may also have had a formal mixed meal tolerance test with post meal blood sugar <60 mg/dL.
2. Subjects who otherwise meet the study criteria above with hypoglycemia symptoms but who do not have documented hypoglycemia by plasma measurement may undergo a screening visit to document the requisite levels for consideration into the study.

Exclusion criteria

1. Chronic or acute diseases of the liver.
2. Chronic or acute diseases of the pancreas (including type 1 diabetes or pancreatitis or a history of pancreatitis). Subjects may have a diagnosis of type 2 diabetes but must no longer require diabetes medication.
3. Chronic or acute diseases of the kidneys.
4. Known malignancies and must not have a family history of medullary thyroid cancer.
5. History of pre-RYGB hypoglycemia symptoms or low documented plasma glucose preoperatively.
6. Pregnant or plans to become pregnant throughout study duration
7. Breastfeeding
8. Medication exclusions in addition to the current use of diabetes medications. Subjects will be excluded if they have previously taken GLP-1 agonists.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Quadruple Blind

---

11 participants in 3 patient groups, including a placebo group

Arm 1: Exenatide (5mcg) + Acarbose Placebo

Active Comparator group

Description:

Exenatide (5 mcg) 30 minutes before the high-carb meal is delivered and acarbose placebo immediately prior to the high-carb meal

Treatment:

Drug: Acarbose Placebo

Drug: Exenatide

Arm 2: Exenatide (5mcg) + Acarbose (25mg)

Active Comparator group

Description:

Exenatide (5 mcg) 30 minutes before the high-carb meal is delivered and acarbose (25 mg) immediately prior to the high-carb meal

Treatment:

Drug: Exenatide

Drug: Acarbose

Arm 3: Exenatide Placebo + Acarbose (25mg)

Placebo Comparator group

Description:

Exenatide placebo 30 minutes before the high-carb meal is delivered and acarbose (25 mg) immediately prior to the high-carb meal

Treatment:

Drug: Exenatide Placebo

Drug: Acarbose